Cascadian Therapeutics
May 31, 2017

Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference

SEATTLE, May 31, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Jefferies 2017 Healthcare Conference in New York on Tuesday, June 6, 2017, at 8:00 a.m. Eastern time / 5:00 a.m. Pacific time.

A live audio webcast of the presentation will be available through the "Events & Presentations" page of the "News & Events" section of Cascadian Therapeutics' website at www.cascadianrx.com. An archived edition of the session will be available later that day.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib (also known as ONT-380) is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com